{
    "clinical_study": {
        "@rank": "53639", 
        "arm_group": [
            {
                "arm_group_label": "Iron isomaltoside 1000", 
                "arm_group_type": "Experimental", 
                "description": "Monofer\u00ae 1000 mg IV infusion over 15 minutes"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.9 % saline Infusion over 15 min"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of the study is to evaluate the effect of IV iron isomaltoside 1000\n      compared with placebo on Hb in first-time female donors with p-ferritin below 30 \u00b5g/L"
        }, 
        "brief_title": "A Study of Intravenous Iron Isomaltoside 1000 (Monofer\u00ae) Administered by Infusions to Iron-deficient Blood Donors", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Iron-deficiency", 
        "condition_browse": {
            "mesh_term": "Anemia, Iron-Deficiency"
        }, 
        "detailed_description": {
            "textblock": "At present, clinical efficacy and safety data is available for iron isomaltoside 1000\n      administered to patients with IDA requiring iron therapy. However, there is a need for\n      clinical efficacy and safety data within iron deficiency without anaemia which is e.g.\n      observed in blood donors. Thus, this study is planned to compare the efficacy and safety of\n      parenteral iron isomaltoside 1000 with placebo in female blood donors with a p-ferritin\n      below 30 \u00b5g/L."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women aged \u2265 18 years\n\n          2. First-time donor\n\n          3. P-ferritin < 30 \u00b5g/L\n\n          4. Willingness to participate and signed the informed consent form\n\n        Exclusion Criteria:\n\n          1. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and\n             haemosiderosis)\n\n          2. Known hypersensitivity to any excipients in the investigational drug products\n\n          3. History of drug related allergies\n\n          4. History of severe asthma\n\n          5. Decompensated liver cirrhosis and hepatitis (defined as ALAT > 3 times upper limit of\n             normal)\n\n          6. Active acute or chronic infections (assessed by clinical judgement supplied with\n             White Blood Cells (WBC) and C-Reactive Protein (CRP))\n\n          7. Rheumatoid arthritis with symptoms or signs of active inflammation\n\n          8. Subjects who are pregnant or nursing. In order to avoid pregnancy, women have to be\n             postmenopausal (at least 12 months since last menstruation), surgically sterile, or\n             use one of the following contraceptives during the whole study period and after the\n             study has ended for at least 5 times plasma biological half-life of the\n             investigational medicinal product: intrauterine devices and hormonal contraceptives\n             (contraceptive pills, implants, transdermal patches, vaginal devices, or hormonal\n             injections with prolonged release)\n\n          9. Participation in any other clinical study where the study drug has not passed 5\n             half-lives prior to the screening\n\n         10. Untreated vitamin B12 or folate deficiency\n\n         11. Treated with other IV or oral iron products within 4 weeks prior to the screening\n\n         12. Treated with Erythropoietin (EPO) within 4 weeks prior to the screening\n\n         13. Any other medical condition that, in the opinion of the Investigator, may cause the\n             subject to be unsuitable for the completion of the study or place the subject at\n             potential risk from being in the study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895231", 
            "org_study_id": "P-Monofer-BD-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Iron isomaltoside 1000", 
                "intervention_name": "Iron isomaltoside 1000 (Monofer\u00ae)", 
                "intervention_type": "Drug", 
                "other_name": "Monofer\u00ae"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "0.9 % saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Iron", 
                "Ferric Compounds"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer\u00ae) Administered by Infusions to Iron-Deficient Blood Donors", 
        "overall_contact": {
            "email": "LLT@Pharmacosmos.com", 
            "last_name": "Lars Lykke Thomsen", 
            "phone": "+45 59 48 59 59"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is to measure and compare the change in Hb concentration from baseline to right before the third blood donation in the two study arms", 
            "measure": "Change in Hb concentration", 
            "safety_issue": "No", 
            "time_frame": "From baseline and until t= 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895231"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in Hb concentrations from baseline to right before second donation", 
                "measure": "Change in Hb concentration", 
                "safety_issue": "No", 
                "time_frame": "From baseline and until t=3 months"
            }, 
            {
                "description": "Number of subjects who cannot complete three donations due to low Hb", 
                "measure": "Ability to complete 3 blood donations", 
                "safety_issue": "No", 
                "time_frame": "From baseline and until t=6 months"
            }, 
            {
                "measure": "Change in p-iron", 
                "safety_issue": "No", 
                "time_frame": "From baseline and until week 12"
            }, 
            {
                "measure": "Change in fatigue symptoms", 
                "safety_issue": "No", 
                "time_frame": "From baseline and until week 12"
            }, 
            {
                "description": "Change in exercise tolerance from baseline to 3 weeks after baseline measured by a two-step test on bike", 
                "measure": "Exercise tolerance", 
                "safety_issue": "No", 
                "time_frame": "From baseline to week 3"
            }, 
            {
                "measure": "Number of adverse drug reactions", 
                "safety_issue": "Yes", 
                "time_frame": "From screening and until t= 6 months"
            }, 
            {
                "measure": "Change in p-ferritin", 
                "safety_issue": "No", 
                "time_frame": "From baseline and until week 12"
            }, 
            {
                "measure": "Change in Transferrin Saturation (TSAT)", 
                "safety_issue": "No", 
                "time_frame": "From baseline until week 12"
            }, 
            {
                "measure": "Change in reticulocyte count", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to week 12"
            }, 
            {
                "measure": "Change in haematology parameters", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline and until t= 6 months"
            }, 
            {
                "measure": "Change in RLS symptoms", 
                "safety_issue": "No", 
                "time_frame": "From baseline and until t= 6 months"
            }
        ], 
        "source": "Pharmacosmos A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "Max Neeman", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Pharmacosmos A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}